ARCTURUS THERAPEUTICS HOLDINGS INC. Financials Arcturus Therapeutics Holdings Inc.
Equities
ARCT
US03969T1097
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.81 USD | +0.86% |
|
+27.62% | +23.09% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 164.5 | 1,122 | 975.6 | 450.4 | 842.6 | 1,045 | - | - |
| Enterprise Value (EV) 1 | 164.5 | 672.7 | 668.2 | 149.4 | 576.5 | 708.9 | 1,045 | 1,045 |
| P/E ratio | -5.06 x | -12.2 x | -4.78 x | 48.5 x | -31.5 x | -13 x | -25.2 x | 20.6 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 7.92 x | 118 x | 78.9 x | 2.19 x | 4.96 x | 5.75 x | 4.56 x | 2.7 x |
| EV / Revenue | 7.92 x | 70.5 x | 54.1 x | 0.73 x | 3.39 x | 3.9 x | 4.56 x | 2.7 x |
| EV / EBITDA | - | - | -3.31 x | 10.9 x | -7.99 x | -8.5 x | -10.3 x | -6.44 x |
| EV / FCF | - | -15,081,355 x | -2,827,861 x | - | - | - | -7,652,330 x | -12,911,015 x |
| FCF Yield | - | -0% | -0% | - | - | - | -0% | -0% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 15,138 | 25,858 | 26,361 | 26,555 | 26,723 | 26,932 | - | - |
| Reference price 2 | 10.87 | 43.38 | 37.01 | 16.96 | 31.53 | 38.81 | 38.81 | 38.81 |
| Announcement Date | 3/11/20 | 3/1/21 | 2/28/22 | 3/28/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 20.79 | 9.539 | 12.36 | 206 | 169.9 | 181.8 | 229.3 | 386.6 |
| EBITDA 1 | - | - | -201.7 | 13.7 | -72.11 | -83.39 | -101.8 | -162.2 |
| EBIT 1 | -25.51 | -71.52 | -202.9 | 12.18 | -75.07 | -92.23 | -56.54 | 65.1 |
| Operating Margin | -122.72% | -749.81% | -1,641.33% | 5.91% | -44.18% | -50.72% | -24.65% | 16.84% |
| Earnings before Tax (EBT) 1 | -25.99 | -72.15 | -203.7 | 10.64 | -24.76 | -66 | -44.76 | 51.4 |
| Net income 1 | -25.99 | -72.15 | -203.7 | 9.349 | -26.59 | -81.25 | -47.38 | 47.83 |
| Net margin | -125.02% | -756.35% | -1,647.98% | 4.54% | -15.65% | -44.68% | -20.66% | 12.37% |
| EPS 2 | -2.150 | -3.550 | -7.740 | 0.3500 | -1.000 | -2.990 | -1.542 | 1.887 |
| Free Cash Flow | - | -44.6 | -236.3 | - | - | - | -136.6 | -80.96 |
| FCF margin | - | -467.59% | -1,911.95% | - | - | - | -59.56% | -20.94% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/11/20 | 3/1/21 | 2/28/22 | 3/28/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.794 | 5.244 | 27.09 | 13.37 | 160.3 | 80.28 | 10.52 | 45.14 | 33.99 | 38.01 | 22.23 | 44.3 | 69.95 | 50.59 | 58.22 |
| EBITDA 1 | - | - | - | - | - | - | - | - | -14.32 | -29.51 | -38.92 | -12.2 | -7.653 | - | - |
| EBIT 1 | -37.64 | -50.38 | -22.09 | -36.81 | 121.5 | 14.76 | -55.37 | -19.31 | -15.14 | -30.41 | -43.35 | -25.2 | 2.985 | -25.93 | -12.25 |
| Operating Margin | -649.72% | -960.7% | -81.53% | -275.32% | 75.77% | 18.38% | -526.42% | -42.79% | -44.54% | -80.01% | -194.99% | -56.9% | 4.27% | -51.26% | -21.05% |
| Earnings before Tax (EBT) 1 | -38.66 | -51.17 | -21.56 | -35.27 | 118.6 | 50.86 | -51.97 | -15.33 | -8.311 | -26.45 | -41.26 | -23.29 | 5.003 | -26.08 | -12.4 |
| Net income 1 | -38.66 | -51.17 | -21.56 | -35.27 | 117.3 | 50.75 | -52.55 | -16.22 | -8.573 | -26.82 | -41.3 | -23.33 | 4.96 | -26.08 | -12.4 |
| Net margin | -667.31% | -975.76% | -79.59% | -263.79% | 73.21% | 63.22% | -499.57% | -35.94% | -25.22% | -70.55% | -185.75% | -52.67% | 7.09% | -51.56% | -21.31% |
| EPS 2 | -1.470 | -1.940 | -0.8200 | -1.330 | 4.330 | 1.870 | -1.980 | -0.6100 | -0.3200 | -1.000 | -1.605 | -0.7967 | 0.1184 | -0.8375 | -0.7175 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/22 | 5/9/22 | 8/9/22 | 11/9/22 | 3/28/23 | 5/9/23 | 8/7/23 | 11/14/23 | 3/7/24 | 5/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 449 | 307 | 301 | 266 | 336 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | -44.6 | -236 | - | - | - | -137 | -81 |
| ROE (net income / shareholders' equity) | - | - | -65.2% | 3.75% | -9.64% | -34.4% | -74.3% | -75.4% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.82 | 1.74 | - | 7.73 | 2.9 | 8 | 6.61 | 7.17 |
| Capex / Sales | 3.93% | 18.26% | - | 3.75% | 1.71% | 4.4% | 2.88% | 1.85% |
| Announcement Date | 3/11/20 | 3/1/21 | 2/28/22 | 3/28/23 | 3/7/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
38.81
USD
Average target price
72.25
USD
Spread / Average Target
+86.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.09% | 1.05B | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- ARCT Stock
- Financials Arcturus Therapeutics Holdings Inc.
